iclaprim has been researched along with Skin Diseases, Bacterial in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amin, F; Corey, GR; Dryden, M; File, TM; Heller, B; Holland, TL; Huang, DB; McLeroth, P; O'Riordan, W; Overcash, JS; Shukla, R; Torres, A; Wilcox, MH | 1 |
| Borghei, A; Corey, GR; Dryden, M; File, TM; Holland, TL; Huang, DB; Lodise, T; McLeroth, P; McManus, A; O'Riordan, W; Oguri, T; Shin, E; Shukla, R; Torres, A; Wilcox, MH | 1 |
| Dryden, M; Huang, DB | 1 |
| Balser, B; Corey, GR; Desplats, E; Dryden, M; File, TM; Holland, TL; Huang, DB; Lodise, T; O'Riordan, W; Torres, A; Wilcox, MH | 1 |
| Balser, B; Corey, GR; Huang, DB; Noviello, S; Scaramucci, A | 1 |
| Cofer, C; Morgan, A; Stevens, DL | 1 |
| Cabeza, J; Carrasco, C; Gutierrez, J; Sorlozano, A; Villegas, E | 1 |
2 review(s) available for iclaprim and Skin Diseases, Bacterial
| Article | Year |
|---|---|
Iclaprim, a dihydrofolate reductase inhibitor antibiotic in Phase III of clinical development: a review of its pharmacology, microbiology and clinical efficacy and safety.
Topics: Administration, Intravenous; Anti-Bacterial Agents; Clinical Trials, Phase III as Topic; Drug-Related Side Effects and Adverse Reactions; Folic Acid Antagonists; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pyrimidines; Skin Diseases, Bacterial; Treatment Outcome | 2018 |
Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections.
Topics: Anti-Bacterial Agents; Clinical Trials as Topic; Gram-Positive Bacterial Infections; Humans; Pyrimidines; Skin Diseases, Bacterial; Soft Tissue Infections | 2009 |
4 trial(s) available for iclaprim and Skin Diseases, Bacterial
| Article | Year |
|---|---|
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Path
Topics: Administration, Intravenous; Adult; Anti-Bacterial Agents; Double-Blind Method; Female; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Male; Middle Aged; Pyrimidines; Skin; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin | 2018 |
A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Path
Topics: Administration, Intravenous; Adult; Aged; Female; Gram-Positive Bacteria; Humans; Male; Middle Aged; Pyrimidines; Skin Diseases, Bacterial; Vancomycin | 2018 |
Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections.
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Creatinine; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Patient Safety; Pyrimidines; Skin Diseases, Bacterial; Staphylococcal Infections; Staphylococcus aureus; Streptococcal Infections; Streptococcus pyogenes; Treatment Outcome; Vancomycin | 2018 |
A Pooled Analysis of the Safety and Efficacy of Iclaprim Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Patients With Intravenous Drug Use: Phase 3 REVIVE Studies.
Topics: Administration, Intravenous; Anti-Bacterial Agents; Double-Blind Method; Humans; Pyrimidines; Skin Diseases, Bacterial; Substance Abuse, Intravenous; Treatment Outcome; Vancomycin | 2019 |
1 other study(ies) available for iclaprim and Skin Diseases, Bacterial
| Article | Year |
|---|---|
Antimicrobial development in the era of emerging resistance.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Bacteria; beta-Lactams; Cephalosporins; Drug Approval; Drug Resistance, Bacterial; Glycopeptides; Humans; Lipoglycopeptides; Pyrimidines; Skin Diseases, Bacterial; Skin Diseases, Viral; Teicoplanin; United States; United States Food and Drug Administration | 2009 |